Solar Urticaria: An Ambispective Study in a Long-term Follow-up Cohort with Emphasis on Therapeutic Predictors and Outcomes
DOI:
https://doi.org/10.2340/actadv.v104.25576Keywords:
Chronic urticaria, Inducible urticaria, omalizumab, predictor, solar urticaria, treatmentAbstract
Solar urticaria is a rare photodermatosis with several unknown pathogenic, clinical and therapeutic aspects. This study analysed the clinical and therapeutic features of a long-term follow-up solar urticaria cohort, with a focus on omalizumab management and outcomes, and characterized omalizumab response with the use of the high-affinity immunoglobulin E (IgE) receptor (FcεRI) and the Urticaria Control Test. An observational, unicentric, ambispective study was conducted from 2007 to 2023. Solar urticaria was diagnosed in 41 patients with a median follow-up of 60 months. Thirteen patients were prescribed omalizumab, with a median treatment time of 48 months. A significant decrease in FcεRI baseline levels and subsequent median increase in Urticaria Control Test was evidenced after omalizumab prescription in all patients. Drug survival at 48 months was at 88.9%. Omalizumab stepping-down protocol led to sustained omalizumab discontinuation in only 1 patient. Median basal Urticaria Control Test was lower (p < 0.01) in patients who were prescribed omalizumab and in patients without remission. This study contributes to our knowledge of omalizumab outcomes in real-life clinical practice and highlights the pathogenic importance of IgE-mediated pathways in solar urticaria, where FcεRI emerges as a possible biomarker of omalizumab response.
Downloads
References
Goetze S, Elsner P. Solar urticaria. J Dtsch Dermatol Ges 2015; 13: 1250-1253.
https://doi.org/10.1111/ddg.12809 DOI: https://doi.org/10.1111/ddg.12809
McSweeney SM, Sarkany R, Fassihi H, Tziotzios C, McGrath JA. Pathogenesis of solar urticaria: Classic perspectives and emerging concepts. Exp Dermatol 2022; 31: 586-593.
https://doi.org/10.1111/exd.14493 DOI: https://doi.org/10.1111/exd.14493
McSweeney SM, Kloczko E, Chadha M, Sarkany R, Fassihi H, Tziotzios C, et al. Systematic review of the clinical characteristics and natural history of solar urticaria. J Am Acad Dermatol 2023; 89: 138-140.
https://doi.org/10.1016/j.jaad.2023.01.039 DOI: https://doi.org/10.1016/j.jaad.2023.01.039
Haylett AK, Koumaki D, Rhodes LE. Solar urticaria in 145 patients: assessment of action spectra and impact on quality of life in adults and children. Photodermatol Photoimmunol Photomed 2018; 34: 262-268.
https://doi.org/10.1111/phpp.12385 DOI: https://doi.org/10.1111/phpp.12385
Yu M, Terhorst-Molawi D, Altrichter S, Hawro T, Chen YD, Liu B, et al. Omalizumab in chronic inducible urticaria: a real-life study of efficacy, safety, predictors of treatment outcome and time to response. Clin Exp Allergy 2021; 51: 730-734.
https://doi.org/10.1111/cea.13838 DOI: https://doi.org/10.1111/cea.13838
Maurer M, Raap U, Staubach P, Richter-Huhn G, Bauer A, Oppel EM, et al. Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study. Clin Exp Allergy 2019; 49: 655-662.
https://doi.org/10.1111/cea.13309 DOI: https://doi.org/10.1111/cea.13309
Maurer M, Church MK, Gonçalo M, Sussman G, Sánchez-Borges M. Management and treatment of chronic urticaria (CU). J Eur Acad Dermatol Venereol 2015; 29: 16-32.
https://doi.org/10.1111/jdv.13198 DOI: https://doi.org/10.1111/jdv.13198
Aubin F, Avenel-Audran M, Jeanmougin M, Adamski H, Peyron JL, Marguery MC, et al. Omalizumab in patients with severe and refractory solar urticaria: a phase II multicentric study. J Am Acad Dermatol 2016; 74: 574-575.
https://doi.org/10.1016/j.jaad.2015.11.021 DOI: https://doi.org/10.1016/j.jaad.2015.11.021
Maurer M, Metz M, Brehler R, Hillen U, Jakob T, Mahler V, et al. Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence. J Allergy Clin Immunol 2018; 141: 638-649.
https://doi.org/10.1016/j.jaci.2017.06.032 DOI: https://doi.org/10.1016/j.jaci.2017.06.032
Snast I, Kremer N, Lapidoth M, Enk CD, Tal Y, Rosman Y, et al. Omalizumab for the treatment of solar urticaria: case series and systematic review of the literature. J Allergy Clin Immunol Pract 2018; 6: 1198-1204.e3.
https://doi.org/10.1016/j.jaip.2018.02.032 DOI: https://doi.org/10.1016/j.jaip.2018.02.032
Navarro-Triviño FJ, Prados-Carmona A, Aguilera J, de Gálvez MV, Ruiz-Villaverde R. Treatment of refractory solar urticaria: could dupilumab fill the current gap? J Dtsch Dermatol Ges 2023; 21: 652-653.
https://doi.org/10.1111/ddg.15025 DOI: https://doi.org/10.1111/ddg.15025
Deza G, Bertolín-Colilla M, Pujol RM, Curto-Barredo L, Soto D, García M, et al. Basophil FcεRI expression in chronic spontaneous urticaria: a potential immunological predictor of response to omalizumab therapy. Acta Derm Venereol 2017; 97: 698-704.
https://doi.org/10.2340/00015555-2654 DOI: https://doi.org/10.2340/00015555-2654
Moñino-Romero S, Kolkhir P, Ohanyan T, Szépfalusi Z, Weller K, Metz M, et al. Elevated baseline soluble FcεRI may be linked to early response to omalizumab treatment in chronic spontaneous urticaria. J Eur Acad Dermatol Venereol 2024; 38: 167-174.
https://doi.org/10.1111/jdv.19485 DOI: https://doi.org/10.1111/jdv.19485
Spertino J, Curto-Barredo L, Rozas-Muñoz E, Figueras-Nart I, Gimenez-Arnau A, Serra-Baldrich E, et al. Algorithm for treatment of chronic spontaneous urticaria with omalizumab. Actas Dermosifiliogr (Engl Ed) 2018; 109: 771-776. DOI: https://doi.org/10.1016/j.adengl.2018.09.011
https://doi.org/10.1016/j.ad.2018.07.005 DOI: https://doi.org/10.1016/j.ad.2018.07.005
De Argila D, Aguilera J, Sánchez J, García-Díez A. Study of idiopathic, exogenous photodermatoses, part II: photobiologic testing. Actas Dermosifiliogr 2014; 105: 233-242. DOI: https://doi.org/10.1016/j.adengl.2012.07.040
https://doi.org/10.1016/j.ad.2012.07.024 DOI: https://doi.org/10.1016/j.ad.2012.07.024
Pérez-Ferriols A, Aguilera J, Aguilera P, de Argila D, Barnadas MA, de Cabo X, et al. Determination of minimal erythema dose and anomalous reactions to UVA radiation by skin phototype. Actas Dermosifiliogr 2014; 105: 780-788.
https://doi.org/10.1016/j.adengl.2014.05.020 DOI: https://doi.org/10.1016/j.adengl.2014.05.020
Magerl M, Altrichter S, Borzova E, Giménez-Arnau A, Grattan CE, Lawlor F, et al. The definition, diagnostic testing, and management of chronic inducible urticarias - the EAACI/GA(2) LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy 2016; 71: 780-802.
https://doi.org/10.1111/all.12884 DOI: https://doi.org/10.1111/all.12884
Morgado-Carrasco D, Fustà-Novell X, Podlipnik S, Combalia A, Aguilera P. Clinical and photobiological response in eight patients with solar urticaria under treatment with omalizumab, and review of the literature. Photodermatol Photoimmunol Photomed 2018; 34: 194-199.
https://doi.org/10.1111/phpp.12370 DOI: https://doi.org/10.1111/phpp.12370
Snast I, Lapidoth M, Uvaidov V, Enk CD, Mazor S, Hodak E, et al. Real-life experience in the treatment of solar urticaria: retrospective cohort study. Clin Exp Dermatol 2019; 44: e164-e170.
https://doi.org/10.1111/ced.13960 DOI: https://doi.org/10.1111/ced.13960
Photiou L, Foley P, Ross G. Solar urticaria - an Australian case series of 83 patients. Australas J Dermatol 2019; 60: 110-117.
https://doi.org/10.1111/ajd.12975 DOI: https://doi.org/10.1111/ajd.12975
Kishimoto I, Uetsu N, Tanimura H, Fujii H, Okamoto H. Solar urticaria with a wide action spectrum from UVB to visible light complicated with UVA-induced polymorphous light eruption. Photodermatol Photoimmunol Photomed 2017; 33: 172-175.
https://doi.org/10.1111/phpp.12300 DOI: https://doi.org/10.1111/phpp.12300
Pesqué D, March-Rodríguez Á, Curto-Barredo L, Soto D, Gimeno R, Pujol RM, et al. Autoimmune diseases and low baseline immunoglobulin E in chronic spontaneous urticaria: a clinical and therapeutic prospective analysis in real clinical practice. J Allergy Clin Immunol Pract 2023; 11: 3763-3771.e5
https://doi.org/10.1016/j.jaip.2023.09.002 DOI: https://doi.org/10.1016/j.jaip.2023.09.002
Lin H, Boesel KM, Griffith DT, Prussin C, Foster B, Romero FA, et al. Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils. J Allergy Clin Immunol 2004; 113: 297-302.
https://doi.org/10.1016/j.jaci.2003.11.044 DOI: https://doi.org/10.1016/j.jaci.2003.11.044
Oliver JM, Tarleton CA, Gilmartin L, Archibeque T, Qualls CR, Diehl L, et al. Reduced FcεRI-mediated release of asthma- promoting cytokines and chemokines from human basophils during omalizumab therapy. Int Arch Allergy Immunol 2010; 151: 275-284.
https://doi.org/10.1159/000250436 DOI: https://doi.org/10.1159/000250436
Wright JD, Chu HM, Huang CH, Ma C, Chang TW, Lim C. Structural and physical basis for anti-IgE therapy. Sci Rep 2015; 5: 11581.
https://doi.org/10.1038/srep11581 DOI: https://doi.org/10.1038/srep11581
Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB. Omalizumab treatment downregulates dendritic cell FcεRI expression. J Allergy Clin Immunol 2003; 112: 1147-1154
https://doi.org/10.1016/j.jaci.2003.10.003 DOI: https://doi.org/10.1016/j.jaci.2003.10.003
Kocatürk E, Can PK, Akbas PE, Copur M, Degirmentepe EN, Kızıltac K, et al. Management of chronic inducible urticaria according to the guidelines: a prospective controlled study. J Dermatol Sci 2017; 87: 60-69.
https://doi.org/10.1016/j.jdermsci.2017.02.283 DOI: https://doi.org/10.1016/j.jdermsci.2017.02.283
Morgado-Carrasco D, Giácaman-Von der Weth M, Fustá-Novell X, Podlipnik S, Pérez-Ferriols A, Aguilera P. Clinical response and long-term follow-up of 20 patients with refractory solar urticaria under treatment with omalizumab. J Am Acad Dermatol 2023; 88: 1110-1111.
https://doi.org/10.1016/j.jaad.2019.05.070 DOI: https://doi.org/10.1016/j.jaad.2019.05.070
Vollono L, Bianchi L, Piccolo A, Mazzilli S, Campione E, Diluvio L Good things come to those who wait: Successful response of solar urticaria to omalizumab after 1 year of treatment. Photodermatol Photoimmunol Photomed 2020; 36: 408-411.
https://doi.org/10.1111/phpp.12577 DOI: https://doi.org/10.1111/phpp.12577
Spekhorst LS, van den Reek JMPA, Knulst AC, Röckmann H. Determinants of omalizumab drug survival in a long-term daily practice cohort of patients with chronic urticaria. Allergy 2019; 74: 1185-1187.
https://doi.org/10.1111/all.13714 DOI: https://doi.org/10.1111/all.13714
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 David Pesqué, Andrea Ciudad, Evelyn Andrades, Dulce Soto, Ramon Gimeno, Ramon M. Pujol, Ana M. Giménez-Arnau
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
